Consistent with these findings, we demonstrated that inhibition of TIM-3 by mAb therapy slows tumor progression in a CT26 mouse model of human colorectal cancer and that this antitumor effect is achieved by reversing T-cell exhaustion. Here, HAVCR2 is linked to colorectal cancer.